Department of Internal Medicine, Division of Cardiovascular Medicine, Michigan Medicine, Ann Arbor, MI, USA.
Department of Internal Medicine, Division of Cardiovascular Medicine, Michigan Medicine, Ann Arbor, MI, USA.
Eur J Pharmacol. 2021 May 5;898:173988. doi: 10.1016/j.ejphar.2021.173988. Epub 2021 Mar 2.
There is a need for therapeutic approaches to prevent and mitigate the effects of Coronavirus Disease (2019) (COVID-19). The histone deacetylase (HDAC) inhibitor valproic acid, which has been available for the therapy of epilepsy for many years, is a drug that could be repurposed for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. This article will review the reasons to consider valproic acid as a potential therapeutic to prevent severe COVID-19. Valproic acid could reduce angiotensin-converting enzyme 2 and transmembrane serine protease 2 expression, required for SARS-CoV-2 viral entry, and modulate the immune cellular and cytokine response to infection, thereby reducing end-organ damage. The combined anti-thrombotic, anti-platelet, and anti-inflammatory effects of valproic acid suggest it could be a promising therapeutic target for COVID-19.
需要采取治疗方法来预防和减轻 2019 年冠状病毒病（COVID-19）的影响。组蛋白去乙酰化酶（HDAC）抑制剂丙戊酸已可用于治疗癫痫多年，是一种可用于严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染患者的药物。本文将回顾考虑丙戊酸作为预防严重 COVID-19 的潜在治疗方法的原因。丙戊酸可降低血管紧张素转换酶 2 和跨膜丝氨酸蛋白酶 2 的表达，这是 SARS-CoV-2 病毒进入所需的，并且可以调节感染的免疫细胞和细胞因子反应，从而减少终末器官损伤。丙戊酸的联合抗血栓形成、抗血小板和抗炎作用表明它可能是 COVID-19 的有前途的治疗靶点。
